{"id":4423,"date":"2026-04-08T18:46:24","date_gmt":"2026-04-08T18:46:24","guid":{"rendered":"https:\/\/stakebridgeirpr.com\/media\/?p=4423"},"modified":"2026-04-08T18:46:24","modified_gmt":"2026-04-08T18:46:24","slug":"fidson-earnings-surge-on-local-manufacturing-expansion","status":"publish","type":"post","link":"https:\/\/stakebridgeirpr.com\/media\/fidson-earnings-surge-on-local-manufacturing-expansion\/","title":{"rendered":"Fidson Earnings Surge On Local Manufacturing Expansion"},"content":{"rendered":"

By Johnson Emmanuel<\/strong><\/p>\n

 <\/p>\n

Fidson Healthcare Plc delivered its strongest financial performance in three years, with revenue rising to N119.1 billion and profit after tax reaching N9.3 billion for the 2025 financial year, driven by strong demand and expanded local manufacturing capacity.<\/p>\n

The company\u2019s 2025 performance reflects a strategic shift towards domestic production amid persistent cost pressures.<\/p>\n

The company recorded sustained growth across ethical drugs, over-the-counter medicines, and consumer healthcare segments, despite macroeconomic pressures including inflation, foreign exchange constraints, and elevated borrowing costs.<\/p>\n

DECISION HIGHLIGHT<\/strong>
\nThe performance is driven by a dual strategy of revenue expansion and increased investment in local manufacturing capacity.<\/p>\n

Management increased capital expenditure to N7.8 billion, more than doubling prior year investment, signalling a structural shift towards domestic production and reduced import dependence.<\/p>\n

DECISION MEMO <\/strong>
\nFidson Healthcare Plc\u2019s 2025 performance reflects a transition from opportunistic growth to capacity-led expansion. The company is not merely scaling sales but restructuring its cost and supply chain exposure through local manufacturing investment.<\/p>\n

Revenue growth, from N53.1 billion in 2023 to N119.1 billion in 2025, indicates strong demand capture in a market undergoing structural change. The exit or scaling down of multinational pharmaceutical firms has created space for domestic players to expand market share.<\/p>\n

Gross profit expansion, despite rising input and logistics costs, suggests pricing power and improved product mix. However, cost pressures remain embedded within the operating environment, particularly in finance costs, which rose to N7.1 billion due to high interest rates.<\/p>\n

The improvement in operating cash flow, from a deficit of N505 million to a surplus of N13.4 billion, indicates stronger internal efficiency. Working capital discipline, particularly in receivables and inventory management, has enhanced liquidity and reduced reliance on external funding.<\/p>\n

The increased capital expenditure is strategically significant. By investing in property, plant, and equipment, the company is positioning itself to mitigate foreign exchange volatility and supply chain disruptions linked to imported inputs.<\/p>\n

Balance sheet strength reinforces this trajectory. Equity growth to N30.8 billion and stable liabilities suggest a more resilient capital structure, even as the company expands operations.<\/p>\n

The broader implication is that local pharmaceutical manufacturers are transitioning into primary industry drivers, supported by policy direction and market demand.<\/p>\n

DATA BOX<\/strong><\/p>\n